Orphan drug specialist Horizon looks to double down on its gout expertise with acquired rights to Arrowhead's RNAi med

Horizon Therapeutics has made a name for taking orphan drugs once left on the scrap heap and spinning them into approved therapies. Along the way, the biotech has picked up an expertise in gout with bestselling Krystexxa, and now it’s looking to double down in that space with a licensing deal for an Arrowhead drug.